The efficacy and safety profile of methadone for intractable cancer pain in advanced lung cancer patients: a single-center retrospective analysis of 37 Japanese patients.

BACKGROUND For patients suffering from intractable cancer pain, which cannot be sufficiently relieved even with strong opioid analgesics, methadone is recommended in Japan. However, the real-world data on the efficacy and safety of methadone for intractable pain in patients with lung cancer remain scarce in clinical setting. The aim of this clinical study was to investigate the efficacy and safety of methadone for intractable pain in advanced lung cancer patients. METHODS All the cases of advanced lung cancer patients who were administered methadone for intractable pain at the Shizuoka Cancer Center between September 2014 and December 2022 were extracted, and their medical information in the electronic medical records were examined. We investigated pain intensity in Numeric Rating Score (NRS) on the day before and 5 days after the initiation of methadone administration, when methadone blood levels were expected to reach a plateau. In addition, the adverse events possibly caused by methadone were also investigated. RESULTS AND CONCLUSIONS Methadone was prescribed for intractable pain in 37 patients with advanced lung cancer during the study period. The leading cause of intractable pain was bone metastasis (including invasion). Both the pain intensity in NRS and the number of rescue doses were significantly reduced by the introduction of methadone (P < .001). In only two patients, methadone was discontinued due to the side effects thought to be caused by this drug. The results of this study indicated the favorable efficacy and safety profile of methadone for intractable pain in patients with advanced lung cancer.

• Publication year

  2025

• Venue

  Japanese Journal of Clinical Oncology

• Publication date

  2025-11-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/jjco/hyaf175PMID 41215487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Low-dose add-on methadone for cancer pain management: a retrospective analysis of 102 Japanese patients.

  2024cited by this paper
• Opioid metabolism and drug-drug interaction in cancer

  2024cited by this paper
• Safety and Efficacy of Combined Injection of Pure-μ-Opioid Agonist with Tramadol as an Opioid Induction Agent for Opioid-Naïve Cancer Patients

  2024cited by this paper
• Differences in the Analgesic Effect of Opioids on Pain in Cancer Patients With Spinal Metastases

  2023cited by this paper
• Methadone switching for refractory cancer pain

  2022cited by this paper
• Lung cancer

  2021cited by this paper
• A Randomized Controlled Trial Evaluating the Analgesic Effect of the Combination of Methadone With Morphine for Cancer Related Pain

  2021cited by this paper
• The Use of Low-Dose Methadone as Add-On to Regular Opioid Therapy in Cancer-Related Pain at End of Life: A National Swedish Survey in Specialized Palliative Care

  2020cited by this paper
• Ultralow-Dose Adjunctive Methadone with Slow Titration, Considering Long Half-Life, for Outpatients with Cancer-Related Pain

  2020cited by this paper
• Methadone for Pain Management: A Pharmacotherapeutic Review

  2020cited by this paper
• Comparative pharmacology and toxicology of tramadol and tapentadol

  2018cited by this paper
• [New Opioid Options in Japan - Methadone, Tapentadol and Hydromorphone].

  2018cited by this paper
• Improved Pain Control in Terminally Ill Cancer Patients by Introducing Low-Dose Oral Methadone in Addition to Ongoing Opioid Treatment

  2017cited by this paper
• Methadone as a First-Line Opioid in Cancer Pain Management: A Systematic Review.

  2017cited by this paper
• Methadone as a Coanalgesic for Palliative Care Cancer Patients

  2016cited by this paper
• Use of Methadone as an Adjuvant Medication to Low-Dose Opioids for Neuropathic Pain in the Frail Elderly: A Case Series

  2016cited by this paper
• What is the main mechanism of tramadol?

  2015cited by this paper
• The Mu-Opioid Receptor Agonist/Noradrenaline Reuptake Inhibition (MOR–NRI) Concept in Analgesia: The Case of Tapentadol

  2014cited by this paper
• Opioids for neuropathic pain.

  2013cited by this paper
• Addition of Methadone to Another Opioid in the Management of Moderate to Severe Cancer Pain: A Case Series

  2013cited by this paper
• Mechanistic and functional differentiation of tapentadol and tramadol

  2012cited by this paper
• Use of methadone as a coanalgesic: response to McKenna and Nicholson.

  2012cited by this paper
• Clinical Management of Pain in Advanced Lung Cancer

  2012cited by this paper
• Use of methadone as a coanalgesic.

  2011cited by this paper
• Tapentadol in Pain Management

  2011cited by this paper
• Pain, depression, and fatigue as a symptom cluster in advanced cancer.

  2011cited by this paper
• Neuropathic pain features in patients with bone metastases referred for palliative radiotherapy.

  2010cited by this paper
• Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors.

  2006cited by this paper
• Pharmacokinetics of Methadone

  2005cited by this paper
• An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain.

  1999cited by this paper
• Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms

  1994cited by this paper
• Intractable pain with lung cancer

  1987cited by this paper
• A comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancer.

  1986cited by this paper

• No citing papers are available for this paper.